Aerys Biosciences is a clinical-stage biopharmaceutical company advancing next-generation small-molecule therapies for idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH). Headquartered in Stanford Research Park (Palo Alto, California), Aerys operates at the heart of one of the world’s leading biomedical innovation hubs.

Our mission is to transform the treatment of fibro-inflammatory lung diseases by targeting the underlying mechanisms driving fibrosis and vascular remodeling. We bring together a multidisciplinary team of scientists, physicians, and clinical collaborators dedicated to translating our cutting-edge discoveries into therapies for patients with limited options.